Why the study?
Does the TRPV3 agonist carvacrol induce safe and effective hypothermia in conscious rodents?
Does the TRPV3 agonist carvacrol induce safe and effective hypothermia in conscious rodents?
TRPV3 agonism with carvacrol has limited potential for pharmacological induction of hypothermia due to modest efficacy at safe doses and high toxicity at higher doses.
Carvacrol unlikely to advance for hypothermia induction; leaves open whether safer TRPV3 agonists merit further preclinical testing.
Therapeutic hypothermia is a promising new strategy for neuroprotection. However, the methods for safe and effective hypothermia induction in conscious patients are lacking. The current study explored the Transient Receptor Potential Vanilloid 3 (TRPV3) channel activation by the agonist carvacrol as a potential hypothermic strategy. It was found that carvacrol lowers core temperature after intraperitoneal and intravenous administration in mice and rats. However, the hypothermic effect at safe doses was modest, while higher intravenous doses of carvacrol induced a pronounced drop in blood pressure and substantial toxicity. Experiments on the mechanism of the hypothermic effect in mice revealed that it was associated with a decrease in whole-body heat generation, but not with a change in cold-seeking behaviors. In addition, the hypothermic effect was lost at cold ambient temperature. Our findings suggest that although TRPV3 agonism induces hypothermia in rodents, it may have a limited potential as a novel pharmacological method for induction of hypothermia in conscious patients due to suboptimal effectiveness and high toxicity.
No takes yet. Share an insight, caveat, or question.
Feketa et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: